news
FDA approves first-of-a-kind intravesical drug delivery system for bladder cancer
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
List view / Grid view
Anti-Cancer Therapeutics
news
WHO adds cancer and diabetes drugs to its essential medicines list
As an important policy tool, the new editions by the WHO mark a “significant” step in broadening access to new medicines with proven clinical benefits.
news
European decentralised CAR T manufacturing consortium launched
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
news
Merck’s SpringWorks Therapeutics gains European approval for Ogsiveo
The drug is the first treatment for desmoid tumours to be approved in the region.
news
T-cell engagers set to drive immuno-oncology market
Amid intensifying market competition, the next-generation therapies could shape the future of oncology.
news
Gilead partners to advance novel oral oncology drug
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
news
Radioligand therapy could address multiple cancer types
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
article
Engineering scalable iPSC-NK therapies
Stefan Braam, Chief Technology Officer, Cellistic, explores the manufacturing and regulatory challenges of scalable, off-the-shelf iPSC-NK cell therapies.
news
BioNTech and BMS partner to advance oncology deal worth over $10 billion
The agreement involves an immunotherapy candidate with potential to innovate treatment of multiple tumour types, stated BMS.
news
New technology could enhance CAR T therapy manufacture
The innovative device could improve CAR T cell cancer immunotherapy and facilitate its use as a first-line therapy, research suggests.
news
CHMP meeting highlights – May 2025
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
news
Novel breast cancer treatment approach significantly enhances survival
With its detailed safety data for chemotherapy and olaparib to treat early-stage breast cancer, the trial findings could lead to improved patient outcomes.
news
Innovative CAR T therapy could deliver in broader therapeutic settings, research suggests
The novel cell therapy utilises a shortened manufacturing process compared to standard production timelines, offering potential for enhanced therapeutic capability.
news
CHMP meeting highlights – April 2025
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
news
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
The collaboration between Boehringer Ingelheim and Tessellate Bio seeks to address availability of targeted medicines for a cancer type shown to be difficult to treat.
